Currently underserved melanoma therapeutics space offers promising pipeline, with 226 first-in-class programs

Ophthalmological disorders market, which is set to almost double from $13.7 billion in 2015 to $26 billion by 2022 at a compound annual growth rate (CAGR) of 9.48%, will see the entry of a range of new companies over the forecast period as the treatment space is transformed by patent expiries and new product entrants.

Callum Dew, Associate Analyst for GBI Research, explains: “Despite a high attrition rate in oncology indications, it is highly likely that numerous first-in-class products in the melanoma pipeline, many of which are supported by promising preclinical data, will reach the market over the coming decade. This will potentially transform the clinical and commercial landscape, and has far-reaching strategic implications for all market participants.”

While targeted therapies such as Opdivo and Keytruda have made a strong impact on the melanoma space, unmet needs remain, not only with regard to safer and more effective therapies but also for further therapy options for patients with non-cutaneous melanoma.

Dew continues: “It appears that the greatest promise in addressing these needs could come in the form of combining novel therapeutics with currently marketed therapies, in order to provide effective treatment and improve patient survival. These combinations are most likely to comprise of an immunotherapeutic and a targeted therapy, or a combination of multiple targeted therapies. This could create a paradigm shift for future melanoma treatment.”

Combination therapeutics seem likely to radically change the melanoma market over the coming years, which could involve combinations of currently marketed products and new novel programs. In terms of the melanoma deals landscape, the majority of deals involve currently established targets, and there are 176 first-in-class programs not involved in prior deals.

“As attention shifts towards combining drugs, companies with the most promising novel developmental programs may seek strategic consolidations with other companies that have current developmental or marketed products.”

Report Title: Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Request Free Sample Pages: http://www.gbiresearch.com/report-store/market-reports/frontier-pharma/frontier-pharma-melanoma-therapeutics-cytokine-and-multiple-targeted-small-molecules-and-mabs-dominate-pipeline-and-firstinclass-innovation/sample?companyid=opr

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

John Carpenter House, John Carpenter Street, London EC4Y 0AN, UK.

This release was published on openPR.